These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
340 related articles for article (PubMed ID: 18058572)
1. Small-molecule and antibody approaches to molecular chemotherapy of primary brain tumors. Newton HB Curr Opin Investig Drugs; 2007 Dec; 8(12):1009-21. PubMed ID: 18058572 [TBL] [Abstract][Full Text] [Related]
2. Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 1: Growth factor and Ras signaling pathways. Newton HB Expert Rev Anticancer Ther; 2003 Oct; 3(5):595-614. PubMed ID: 14599084 [TBL] [Abstract][Full Text] [Related]
3. Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors. Part 5: apoptosis and cell cycle. Newton HB Expert Rev Anticancer Ther; 2005 Apr; 5(2):355-78. PubMed ID: 15877531 [TBL] [Abstract][Full Text] [Related]
4. Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors. Part 4: p53 signaling pathway. Newton HB Expert Rev Anticancer Ther; 2005 Feb; 5(1):177-91. PubMed ID: 15757449 [TBL] [Abstract][Full Text] [Related]
5. Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents. Bellmunt J; Montagut C; Albiol S; Carles J; Maroto P; Orsola A BJU Int; 2007 Feb; 99(2):274-80. PubMed ID: 17092282 [TBL] [Abstract][Full Text] [Related]
6. Chemotherapy for glioblastoma: current treatment and future perspectives for cytotoxic and targeted agents. Minniti G; Muni R; Lanzetta G; Marchetti P; Enrici RM Anticancer Res; 2009 Dec; 29(12):5171-84. PubMed ID: 20044633 [TBL] [Abstract][Full Text] [Related]
7. Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis. Newton HB Expert Rev Anticancer Ther; 2004 Feb; 4(1):105-28. PubMed ID: 14748662 [TBL] [Abstract][Full Text] [Related]
8. Role of tyrosine kinase inhibitors in cancer therapy. Arora A; Scholar EM J Pharmacol Exp Ther; 2005 Dec; 315(3):971-9. PubMed ID: 16002463 [TBL] [Abstract][Full Text] [Related]
9. Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors. Part 3: brain tumor invasiveness. Newton HB Expert Rev Anticancer Ther; 2004 Oct; 4(5):803-21. PubMed ID: 15485315 [TBL] [Abstract][Full Text] [Related]
10. Small molecule inhibitors in children with malignant gliomas. Herrington B; Kieran MW Pediatr Blood Cancer; 2009 Sep; 53(3):312-7. PubMed ID: 19434732 [TBL] [Abstract][Full Text] [Related]
11. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Tabernero J Mol Cancer Res; 2007 Mar; 5(3):203-20. PubMed ID: 17374728 [TBL] [Abstract][Full Text] [Related]
12. Targeting mTOR signaling in lung cancer. Marinov M; Fischer B; Arcaro A Crit Rev Oncol Hematol; 2007 Aug; 63(2):172-82. PubMed ID: 17540577 [TBL] [Abstract][Full Text] [Related]
13. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now. Pang RW; Poon RT Oncology; 2007; 72 Suppl 1():30-44. PubMed ID: 18087180 [TBL] [Abstract][Full Text] [Related]
14. Opportunities and obstacles to combination targeted therapy in renal cell cancer. Sosman JA; Puzanov I; Atkins MB Clin Cancer Res; 2007 Jan; 13(2 Pt 2):764s-769s. PubMed ID: 17255307 [TBL] [Abstract][Full Text] [Related]